Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelicapavir for RSV in HCT Recipients
NCT04633187Phase 2Terminated
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Percentage of Subjects Who Develop Lower Respiratory Tract Complication. Started Jul 2021; status: terminated.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04633187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633187.